This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
zacks-consensus-estimate: Archive
Genpact (G) Upgraded to Buy: Here's Why
by Zacks Equity Research
Genpact (G) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Huron Consulting (HURN) a New Buy Stock
by Zacks Equity Research
Huron Consulting (HURN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Ensign Group (ENSG) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Ensign Group (ENSG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Surf Air Mobility Inc. (SRFM) Upgraded to Buy: Here's Why
by Zacks Equity Research
Surf Air Mobility Inc. (SRFM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Wall Street Analysts Think Amazon (AMZN) Could Surge 30.11%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Amazon (AMZN) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Mama's Creations, Inc. (MAMA) Could Surge 25.18%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 25.2% upside potential for Mama's Creations, Inc. (MAMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 25.55% Upside in SailPoint, Inc. (SAIL): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 25.6% upside potential for SailPoint, Inc. (SAIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 44.75% Upside in Atlassian (TEAM): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Atlassian (TEAM) points to a 44.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 42.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate